Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18149209 | 0.86 | KEAP1 (0.59) | KEAP1NFE2L2CNR1ALPLALDH1A1 | |
| SCHEMBL14395311 | 0.83 | KEAP1 (0.56) | KEAP1NFE2L2CNR1ALPLMEN1 | |
| SCHEMBL4841196 | 0.81 | KEAP1 (0.57) | KEAP1NFE2L2ALPLALDH1A1SMN1; SMN2 | |
| SCHEMBL12773832 | 0.81 | KEAP1 (0.53) | KEAP1NFE2L2CNR1ALPLMEN1 | |
| SCHEMBL20788869 | 0.81 | KEAP1 (0.66) | KEAP1NFE2L2HPGDMAPTNPC1 | |
| SCHEMBL10518552 | 0.79 | KEAP1 (0.69) | KEAP1NFE2L2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL113812 | 0.77 | KEAP1 (1.00) | KEAP1NFE2L2ALPLALDH1A1SMN1; SMN2 | |
| SCHEMBL29744459 | 0.77 | KEAP1 (1.00) | KEAP1NFE2L2ALPLALDH1A1SMN1; SMN2 | |
| SCHEMBL919984 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2ALDH1A1MEN1KMT2A | |
| SCHEMBL31048928 | 0.77 | KEAP1 (0.71) | KEAP1NFE2L2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414136-B2 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ASAHI GLASS COMPANY, LIMITED (JP) | 2008-08-19 | — | — | US | claimed |
| EP-1626045-B1 | PROCESSES FOR PRODUCING 3-SUBSTITUTED 2-CHLORO-5-FLUOROPYRIDINE OR SALT THEREOF | ASAHI GLASS CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7414136-B2 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ASAHI GLASS COMPANY, LIMITED (JP) | 2008-08-19 | — | — | US | disclosed |
| US-20060058529-A1 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ASAHI GLASS COMPANY, LIMITED (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1626045-A1 | PROCESSES FOR PRODUCING 3-SUBSTITUTED 2-CHLORO-5-FLUOROPYRIDINE OR SALT THEREOF | Asahi Glass Company, Limited (JP) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058529-A1 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ARL1, CBR3, ZC3HAV1L | KEAP1 1598/4885NFE2L2 2800/4885CNR1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.